Liehr T, Rautenstrauss B, Grehl H, Bathke K D, Ekici A, Rauch A, Rott H D
Institute of Human Genetics, Erlangen, Germany.
Hum Genet. 1996 Jul;98(1):22-8. doi: 10.1007/s004390050154.
A female patient with clinical signs and symptoms of a demyelinating neuropathy was shown to have a duplication of the 1.5-Mb region on chromosome 17p11.2, typical of the great majority of cases of Charcot-Marie-Tooth disease type 1A (CMT1A). However, analysis of DNA extracted from peripheral blood revealed a 2:2.4 instead of the usual 2:3 ratio between the 7.8- and 6.0-kb EcoRI fragments in the proximal and distal repetitive extragenic palindromic (REP) elements of CMT1A. Detection of a 3.2-kb EcoRI/SacI kb junction fragment with probe pLR7.8 confirmed the CMT1A duplication. The dosage of this junction fragment, compared with a 2.8-kb EcoRI/SacI fragment of the proximal REP elements of CMT1A, was 2:0.58 instead of the expected 2:1 dosage for heterozygous CMT1A duplications. We hypothesized that the lower dosages of these restriction fragments specific for the CMT1A duplication were due to mosaicism; this was confirmed by fluorescence in situ hybridization analysis with the D17S122-specific probe pVAW409R1. In peripheral blood lymphocytes the percentage of interphase nuclei with a duplication in 17p11.2 was 49%. In interphase nuclei extracted from buccal mucosa, hair-root cells or paraffin-embedded nervous tissue the duplication was detectable in 51%, 66% and 74%, respectively. This is the first report of mosaicism in a patient with a CMT1A duplication identified by three different and independent techniques.
一名患有脱髓鞘性神经病临床体征和症状的女性患者,被发现17号染色体p11.2区域存在1.5 Mb的重复,这是大多数1A型夏科-马里-图斯病(CMT1A)病例的典型特征。然而,对外周血提取的DNA分析显示,CMT1A近端和远端重复外显子回文(REP)元件中,7.8 kb和6.0 kb的EcoRI片段比例为2:2.4,而非通常的2:3。用探针pLR7.8检测到一个3.2 kb的EcoRI/SacI连接片段,证实了CMT1A重复。与CMT1A近端REP元件的2.8 kb EcoRI/SacI片段相比,该连接片段的剂量为2:0.58,而非杂合性CMT1A重复预期的2:1剂量。我们推测这些CMT1A重复特异性限制片段剂量较低是由于嵌合体所致;用D17S122特异性探针pVAW409R1进行的荧光原位杂交分析证实了这一点。在外周血淋巴细胞中,17p11.2有重复的间期核百分比为49%。从颊黏膜、发根细胞或石蜡包埋的神经组织中提取的间期核中,重复分别在51%、66%和74%中可检测到。这是首次通过三种不同且独立的技术鉴定出CMT1A重复患者存在嵌合体的报告。